Biomarkers for breast cancer stem cells: The challenges ahead

Biomarkers in Medicine

Volumn 5, Issue 5, 2011, Pages 661-671

  Gkmen Polar, Yesim ^a   Nakshatri, Harikrishna ^a   Badve, Sunil ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IU Health Pathology Laboratory   (United States)

Author keywords

basal stem progenitor; biomarker; breast cancer stem cell; fluorescent activated cell sorting analysis; luminal progenitor; mammosphere assay; mature luminal cell; tumor initiating cell

Indexed keywords

AGAROSE; ALDEHYDE DEHYDROGENASE; CD24 ANTIGEN; CD49 ANTIGEN; CELL SURFACE MARKER; HERMES ANTIGEN; LAPATINIB; LYMPHOCYTE ANTIGEN; PROTEASOME; PROTEIN DLL; PROTEIN DNER; TUMOR MARKER; UNCLASSIFIED DRUG;

AGAROSE MACROBEAD CULTURE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CELL; BREAST EPITHELIUM; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CELL ASSAY; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL LINEAGE; CELL RENEWAL; CULTURE TECHNIQUE; CYTOPLASM; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; MAMMOSPHERE ASSAY; METASTASIS; NONHUMAN; PLURIPOTENT STEM CELL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SOMATIC MUTATION; TREATMENT RESPONSE; XENOTRANSPLANTATION;

ANIMALS; ANTIGENS, CD24; ANTIGENS, CD44; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; ISOENZYMES; NEOPLASTIC STEM CELLS; PROGNOSIS; RETINAL DEHYDROGENASE;

EID: 80054826145     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.57     Document Type: Review

References (99)

1. Weissman IL, Anderson DJ, Gage F. Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Annu. Rev. Cell. Dev. Biol. 17, 387-403 (2001). (Pubitemid 33096181)
2. Morrison SJ, Shah NM, Anderson DJ. Regulatory mechanisms in stem cell biology. Cell 88(3), 287-298 (1997). (Pubitemid 27131370)
3. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3(7), 730-737 (1997). (Pubitemid 27298715)
4. Smith GH. Experimental mammary epithelial morphogenesis in an in vivo model: evidence for distinct cellular progenitors of the ductal and lobular phenotype. Breast Cancer Res. Treat. 39(1), 21-31 (1996). (Pubitemid 26136501)
5. Tsai YC, Lu Y, Nichols PW, Zlotnikov G, Jones PA, Smith HS. Contiguous patches of normal human mammary epithelium derived from a single stem cell: implications for breast carcinogenesis. Cancer Res. 56(2), 402-404 (1996). (Pubitemid 26026371)
6. Kordon EC, Smith GH. An entire functional mammary gland may comprise the progeny from a single cell. Development 125(10), 1921-1930 (1998). (Pubitemid 28274378)
7. Stingl J, Eirew P, Ricketson I, et al. Purification and unique properties of mammary epithelial stem cells. Nature 439(7079), 993-997 (2006). (Pubitemid 43292419)
8. Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell. Nature 439(7072), 84-88 (2006). (Pubitemid 43053633)
9. Sleeman KE, Kendrick H, Ashworth A, Isacke CM, Smalley MJ. CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res. 8(1), R7 (2006).
10. Asselin-Labat ML, Sutherland KD, Barker H, et al. Gatα-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat. Cell. Biol. 9(2), 201-209 (2007). (Pubitemid 46420863)
11. Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, Smalley MJ. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J. Cell. Biol. 176(1), 19-26 (2007). (Pubitemid 46041676)
12. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 7(3), 86-95 (2005). (Pubitemid 40704127)
13. Villadsen R. In search of a stem cell hierarchy in the human breast and its relevance to breast cancer evolution. APMIS 113(11-12), 903-921 (2005). (Pubitemid 43934228)
14. Asselin-Labat ML, Vaillant F, Sheridan JM, et al. Control of mammary stem cell function by steroid hormone signalling. Nature 465(7299), 798-802 (2010).
15. Joshi PA, Jackson HW, Beristain AG, et al. Progesterone induces adult mammary stem cell expansion. Nature 465(7299), 803-807 (2010).
16. Chaffer CL, Brueckmann I, Scheel C, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. USA 108(19), 7950-7955 (2011).
17. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst. 100(9), 672-679 (2008).
18. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl Acad. Sci. USA 106(33), 13820-13825 (2009).
19. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res. 66(4), 1883-1890 (2006).
20. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res. 66(19), 9339-9344 (2006). (Pubitemid 44623625)
21. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 6(19), 2332-2338 (2007). (Pubitemid 350058682)
22. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J. Clin. Oncol. 26(17), 2813-2820 (2008).
23. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100(7), 3983-3988 (2003). (Pubitemid 36418143)
24. Asselin-Labat ML, Shackleton M, Stingl J, et al. Steroid hormone receptor status of mouse mammary stem cells. J. Natl Cancer Inst. 98(14), 1011-1014 (2006). (Pubitemid 44288166)
25. Villadsen R, Fridriksdottir AJ, Ronnov-Jessen L, et al. Evidence for a stem cell hierarchy in the adult human breast. J. Cell. Biol. 177(1), 87-101 (2007). (Pubitemid 46588404)
26. Eirew P, Stingl J, Raouf A, et al. A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat. Med. 14(12), 1384-1389 (2008).
27. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 15(8), 907-913 (2009).
28. Nakshatri H. Radiation resistance in breast cancer: are CD44+/CD24-/proteosome low/ PKH26+ cells to blame? Breast Cancer Res. 12(2), 105 (2010).
29. Nakshatri H, Srour EF, Badve S. Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr. Stem Cell Res. Ther. 4(1), 50-60 (2009).
30. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 11(3), 259-273 (2007). (Pubitemid 46349843)
31. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5), 555-567 (2007). (Pubitemid 350056407)
32. Pece S, Tosoni D, Confalonieri S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140(1), 62-73 (2010).
33. Vlashi E, Kim K, Lagadec C, et al. In vivo imaging, tracking, and targeting of cancer stem cells. J. Natl Cancer Inst. 101(5), 350-359 (2009).
34. Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 8(5), R59 (2006).
35. Horwitz KB, Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J. Clin. Endocrinol. Metab. 93(9), 3295-3298 (2008).
36. Karimi-Busheri F, Rasouli-Nia A, Mackey JR, Weinfeld M. Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res. 12(3), R31 (2010).
37. Croker AK, Goodale D, Chu J, et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J. Cell. Mol. Med. 13(8B), 2236-2252 (2009).
38. Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am. J. Pathol. 176(5), 2131-2138 (2010).
39. Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/ progenitor cell population driving tumorigenesis and invasion. Oncogene 27(47), 6120-6130 (2008).
40. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 16(1), 45-55 (2010).
41. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/ progenitor cells. Genes Dev. 17(10), 1253-1270 (2003). (Pubitemid 36583168)
42. Raouf A, Zhao Y, To K, et al. Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell 3(1), 109-118 (2008).
43. Lim E, Wu D, Pal B, et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res. 12(2), R21 (2010).
44. Kendrick H, Regan JL, Magnay FA, et al. Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics 9, 591 (2008).
45. Cho RW, Wang X, Diehn M, et al. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 26(2), 364-371 (2008). (Pubitemid 351413596)
46. Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE. The mammary progenitor marker CD61/b3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. 68(19), 7711-7717 (2008).
47. Liu JC, Deng T, Lehal RS, Kim J, Zacksenhaus E. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. Cancer Res. 67(18), 8671-8681 (2007). (Pubitemid 47437442)
48. Zhang M, Behbod F, Atkinson RL, et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 68(12), 4674-4682 (2008).
49. Stingl J, Eaves CJ, Kuusk U, Emerman JT. Phenotypic and functional characterization in vitro of a multipotent epithelial cell present in the normal adult human breast. Differentiation 63(4), 201-213 (1998). (Pubitemid 28428734)
50. Stingl J, Eaves CJ, Zandieh I, Emerman JT. Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue. Breast Cancer Res. Treat. 67(2), 93-109 (2001). (Pubitemid 32744490)
51. Gudjonsson T, Villadsen R, Nielsen HL, Ronnov-Jessen L, Bissell MJ, Petersen OW. Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev. 16(6), 693-706 (2002). (Pubitemid 34274039)
52. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 10(2), R25 (2008).
53. Smith BH, Gazda LS, Conn BL, et al. Three-dimensional culture of mouse renal carcinoma cells in agarose macrobeads selects for a subpopulation of cells with cancer stem cell or cancer progenitor properties. Cancer Res. 71(3), 716-724 (2011).
54. Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. The CD44+/CD24- phenotype relates to triple-negative state and unfavorable prognosis in breast cancer patients. Med. Oncol. 28(3), 745-752 (2011).
55. Horiguchi K, Toi M, Horiguchi S, et al. Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients. J. Med. Dent. Sci. 57(2), 165-175 (2010).
56. Kim HJ, Kim MJ, Ahn SH, et al. Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status. Breast 20(1), 78-85 (2011).
57. Li W, Liu F, Lei T, et al. The clinicopathological significance of CD44+/ CD24-/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast. Pathol. Res. Pract. 206(12), 828-834 (2010).
58. Resetkova E, Reis-Filho JS, Jain RK, et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res. Treat. 123(1), 97-108 (2010).
59. Zhou L, Jiang Y, Yan T, et al. The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures. Breast Cancer Res. Treat. 122(3), 795-801 (2010).
60. Tanei T, Morimoto K, Shimazu K, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 15(12), 4234-4241 (2009).
61. Honeth G, Bendahl PO, Ringner M, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 10(3), R53 (2008).
62. Mylona E, Giannopoulou I, Fasomytakis E, et al. The clinicopathologic and prognostic significance of CD44+/CD24-/low and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum. Pathol. 39(7), 1096-1102 (2008).
63. Xiao Y, Ye Y, Yearsley K, Jones S, Barsky SH. The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am. J. Pathol. 173(2), 561-574 (2008).
64. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 11(3), 1154-1159 (2005). (Pubitemid 40175765)
65. Balic M, Lin H, Young L, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12(19), 5615-5621 (2006). (Pubitemid 44629587)
66. Lagadec C, Vlashi E, Della Donna L, et al. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res. 12(1), R13 (2010).
67. Phillips TM, McBride WH, Pajonk F. The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation. J. Natl Cancer Inst. 98(24), 1777-1785 (2006). (Pubitemid 46017929)
68. Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458(7239), 780-783 (2009).
69. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/b-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl Acad. Sci. USA 104(2), 618-623 (2007). (Pubitemid 46123074)
70. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356(3), 217-226 (2007). (Pubitemid 46143225)
71. Creighton CJ, Chang JC, Rosen JM. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J. Mammary Gland Biol. Neoplasia 15(2), 253-260 (2010).
72. Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40(5), 499-507 (2008). (Pubitemid 351601215)
73. Hussenet T, Dembele D, Martinet N, Vignaud JM, du Manoir S. An adult tissue-specific stem cell molecular phenotype is activated in epithelial cancer stem cells and correlated to patient outcome. Cell Cycle 9(2), 321-327 (2010).
74. Mizuno H, Spike BT, Wahl GM, Levine AJ. Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc. Natl Acad. Sci. USA 107(52), 22745-22750 (2010).
75. Fillmore C, Kuperwasser C. Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res. 9(3), 303 (2007).
76. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138(5), 822-829 (2009).
77. Hunter K. Host genetics influence tumour metastasis. Nat. Rev. Cancer 6(2), 141-146 (2006). (Pubitemid 43361546)
78. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 456(7222), 593-598 (2008).
79. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 69(4), 1302-1313 (2009).
80. Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8(5), R76 (2007).
81. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to- mesenchymal transition and stem cell characteristics. Cancer Res. 69(10), 4116-4124 (2009).
82. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4), 704-715 (2008). (Pubitemid 351636299)
83. Bhat-Nakshatri P, Appaiah H, Ballas C, et al. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/ CD24- phenotype. BMC Cancer 10, 411 (2010).
84. Meyer MJ, Fleming JM, Ali MA, Pesesky MW, Ginsburg E, Vonderhaar BK. Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res. 11(6), R82 (2009).
85. Fillmore CM, Gupta PB, Rudnick JA, et al. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc. Natl Acad. Sci. USA 107(50), 21737-21742 (2010).
86. Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320), 98-102 (2010).
87. Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468(7320), 103-107 (2010).
88. Brisken C, Duss S. Stem cells and the stem cell niche in the breast: an integrated hormonal and developmental perspective. Stem Cell Rev. 3(2), 147-156 (2007). (Pubitemid 350129717)
89. Eden JA. Breast cancer, stem cells and sex hormones. Part 3: the impact of the menopause and hormone replacement. Maturitas 68(2), 129-136 (2011).
90. Tanos T, Brisken C. What signals operate in the mammary niche? Breast Dis. 29, 69-82 (2008).
91. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449(7162), 557-563 (2007). (Pubitemid 47525152)
92. Liu S, Ginestier C, Ou SJ, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 71(2), 614-624 (2011).
93. Ginestier C, Liu S, Diebel ME, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 120(2), 485-497 (2010).
94. Buess M, Rajski M, Vogel-Durrer BM, Herrmann R, Rochlitz C. Tumor-endothelial interaction links the CD44+/CD24- phenotype with poor prognosis in early-stage breast cancer. Neoplasia 11(10), 987-1002 (2009).
95. Yang ZJ, Wechsler-Reya RJ. Hitem where they live: targeting the cancer stem cell niche. Cancer Cell 11(1), 3-5 (2007). (Pubitemid 46054521)
96. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl Cancer Inst. 88(20), 1456-1466 (1996). (Pubitemid 26340047)
97. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25(33), 5287-5312 (2007). (Pubitemid 350232263)
98. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 17(3), 313-319 (2011).
99. Vassiliou GS, Cooper JL, Rad R, et al. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat. Genet. 43(5), 470-475 (2011).